期刊名称：THROMBOSIS RESEARCH
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Thrombosis Research
|
Thrombosis Research publishes peer-reviewed original research on thrombosis, hemostasis and fibrinolysis for the international scientific community. Both basic and clinical studies are published. Publication of research, which will lead to novel approaches in diagnosis, therapy, prognosis and prevention of thrombotic and hemorrhagic diseases is given high priority. Topics include biology, physiology and biochemistry of the blood-vascular system; molecular biology; genetics; structure and function of coagulation and fibrinolytic factors; rheological and other physical .properties of blood and thrombi; atherogenesis; thrombogenesis; thromboembolism; thrombolysis and epidemiology of cardiovascular disease; clinical studies of the diagnosis, prevention and treatment of thromboembolism. |
|
Thrombosis Research serves a world-wide audience for the rapid dissemination of "cutting edge" information on thrombosis and hemostasis. In addition to original research, the Journal publishes Brief Communications which are short reports of new work; Letters to the Editors-in-Chief which allow the expression of opinions and criticisms on material published in the Journal and other topics of interest; Editorials which provide comments on matters significant to the readers of the Journal; and Reviews which describe topical and relevant scientific issues. Supplement Issues are devoted to publishing papers presented at national and international conferences.
The Editors-in-Chief, assisted by expert Associate Editors as well as an international editorial board of 48 distinguished members, are committed to the rapid dissemination of high quality, original research aimed at the advancement of knowledge of the nature of the vascular system in hemostasis and the pathogenesis involved in atherogenesis and thrombogenesis.
The Journal is invaluable to scientists-in biology, biochemistry, physiology, biophysics and clinical investigations-interested in basic research and in the treatment, diagnosis and prevention of thrombotic, hemorrhagic and other cardiovascular diseases. Research communications submitted to Thrombosis Research are strictly peer-reviewed, and when accepted, rendered a fast distribution to all major libraries in the world as well as to individual subscribers.
Instructions to Authors
I. SUBMISSION OF COMMUNICATIONS
A. Regular Articles, Brief Communications, Mini-Reports and Mini-Reviews should be submitted on-line via Editorial Manager.
Hardcopy submissions [three complete sets of manuscript plus disk] can be sent to:
Editor in Chief for the Americas (USA, Canada, Mid - and South America):
J.S.Ginsberg, Mc Master University, Department of Medicine, 1200 Main Street West, HSC-3W11, Hamilton, Ontario L8N 3Z5, Canada; Email: thrombo@mcmaster.ca.
Editor-in-Chief for the Rest of the world:
P.M.Sandset, Ulleval University Hospital, Department of Hematology, Hematological Research Lab., N-00407 Oslo, Norway; Fax: +47 221 19040; Email: thrombosis-research@ioks.uio.no.
The manuscripts should be accompanied by a submission letter, signed by the corresponding author, with the following statements: (a) that there has been neither duplicate publication nor submission (elsewhere or to another Editor of Thrombosis Research), and (b) that all authors have read and approved the manuscript.
A copy of the title page (with the Editor's name) should always accompany the manuscript.
B. Letters to the Editors-in-Chief should be submitted online via Editorial Manager. Alternatively, please submit hardcopies as detailed above.
Communication Categories: Several categories of manuscripts will be considered for publication. (1) Original Articles are full length reports of original work . (2) Brief Communications are short reports of new work. (3) Mini-Reports address practical problems in the laboratory and in clinical investigation. (4) Mini-Reviews present a brief description of interesting scientific issues. (5) Letters to the Editors-in-Chief. These contributions should be concerned with matters of opinion and criticism on contributions published in the journal and other matters of interest to researchers in our field. (6) Invited State of the Art Articles are reviews solicited by the Editors-in-Chief. (7) Editorials provide comments on matters significant to the readers of Thrombosis Research. (8) Reports of Scientific Meetings are by invitation of the Editors-in-Chief. (9) Supplement issues may cover various topics in the field of thrombosis and hemostasis. They are approved by the Editors-in-Chief and edited preferably by one of the Editors of Thrombosis Research. In addition to the above categories various News Items and Announcements are printed.
Length of Communications: Authors are asked to limit their (a) Original Articles, Mini-Reviews, and Reports of Scientific Meetings to 10,000 words, (b) Brief Communications to 5,000 words, (c) Mini-Reports to 3,000 words, (d) Letters to the Editors-in-Chief to 1,500 words, and (e) News Items and Announcements to 500 words. Although these limits are not strictly enforced, a page charge of US$ 50 for each additional page exceeding these limits will be billed by the publisher to the authors.
Mailing: Manuscripts should be well packed to avoid damage during mail transport. Use 1st class airmail and when possible, courier mail.
II. TYPING INSTRUCTIONS
General Information: It is the responsibility of the authors to write in standard, grammatical English. Spelling may be British or American, but must be consistent throughout the text, tables and legends to tables and figures. A word count should be provided in the covering letter and on the title page. The whole manuscript, including the Abstract, Reference List, Tables, and Legends to Tables and Figures, should be typed double spaced throughout, on one side of the paper only and with wide margins. Original articles should be organised as follows: (a) Title page; (b) Abstract, Keywords, and Abbreviations; (c) Text with the following sections; Introduction, Materials and Methods, Results, Discussion, Acknowledgments; (d) References; (e) Tables; (f) Table Legends and Figure Legends. The pages should be numbered consecutively; the Title page is page 1, the Abstract page 2, etc. throughout the manuscript (including References, Tables, and Legends to Tables and Figures). Brief Communications have no abstract but a summary at the end of the discussion.
(a) Title Page: Identify the category of the communication on top of the page. Double space and type of brief and descriptive Title of the article, the full Name(s) of the Author(s)(in the format First Name, Initials, and Surname) and the Name and Location of the institution where the research was carried out. A word count of the text should include Tables and Legends. Exclude the Abstract and Reference list. The name, address, telephone and fax numbers and/or e-mail address of the corresponding author should be typed at the bottom of the title page as well as, if necessary, additional addresses of other Authors. To ensure fast and efficient correspondence, all authors are requested to provide e-mail addresses with submitted manuscripts. If the manuscript was presented at a meeting, the name of the organization, the place and the date on which it was read must be indicated.
(b) Abstract Page: Abstracts are required for original articles only. The abstract is essential and the most read part of the paper. It should be informative, not descriptive, and should avoid abbreviations except for units of measure. An abstract for a regular article should not exceed 250 words and should end with the principal conclusions of the study. Structured abstracts are encouraged and should use the following headings: Introduction, Materials and Methods, Results and Conclusions.
Keywords and Abbreviations should follow the abstract and be on the same page (or on a separate page if no abstract). List up to 6 key words for subject indexing, preferably to be taken from Index Medicus. List all abbreviations used.
(c) Text of Articles: The text should be arranged as follows: Introduction, without heading, should state the purpose of the investigation and give a short review of pertinent literature.
Materials and methods should be described in detail with appropriate information about patients or experimental animals. Authors should stipulate that informed consent was obtained when applicable to research on humans, with the comment that the study was approved by the institutional Ethics Committee on human research. Manuscripts reporting animal experiments must include the statement that all animals received care in compliance with the American, European, or any other Convention on Animal Care, with the comment that the study was approved by the institutional Ethics Committee. Generic names of drugs and equipment should be used throughout the manuscript with brand names (proprietary name) and the name and location (city, state, country) of the manufacturer in parentheses when first mentioned in the text.
Results should be reported concisely. Results presented either in tables or figures should be commented on in the text.
Discussion is an interpretation of the results and their significance with reference to pertinent work by other authors. It should be clear and concise. The importance of the study and its limitations should be discussed.
Acknowledgments of financial or personal assistance should be placed at the end of the text.
(d) References: Consecutive numbers in square brackets should be used to indicate references in the text, e.g., [1,2], as part of the text and not raised above it.
The full reference should be cited in a numbered list essentially according to the Vancouver Uniform Requirements (5th ed., Ann Intern Med 1997;126(1):36-47).
References should contain names of all authors in small letters (surnames first followed by initials), Title of communication in lower case lettering, Title of Journal [abbreviated according to International Serials Data System-List of Serial title Word Abbreviations, 1985 (ISDS-ISO International Centre, 20 rue Bachaumont, 75002 Paris, France)], year of publication; volume number: first and last page number (see Ref.1).
Reference to Journal Supplement, cf. example (Ref. 2).
References to books should contain Author Name(s) in the same format as above: Title. Publisher's location: Name; Year of publication. page range (see Ref. 3).
References to multi-author books with editor(s) should contain Author Name(s) in the same format as above: Title of contribution. In: Name(s) of editor(s). Title of book. Publisher's location: Name; Year of publication. If necessary page range (see Ref. 4)
For communications which have been accepted for publication, but not yet printed, the reference must contain the journal name and year (see Ref. 5).
Material referred to by the phrase "personal communication" or "submitted for publication" are not considered full references and should only be placed in parentheses at the appropriate place in the text, e.g., (Hessel 1997 personal communication).
Examples of references are shown below.
1. Ordljin TM, Shainoff JR, Lawrence SO, and Simpson-Haidaris PJ. Thrombin cleavage enhances exposure of heparin binding domain in the N-terminus of the fibrin beta chain. Blood 1996;88:2050-61.
2. Copley AL. The endoendothelial fibrin lining. Thromb Res 1983;(SV):1-154.
3. Davies JT, Rideal EK. Interfacial Phenomena. New York-London: Academic Press; 1961. p. 110-30.
4. Blomback B. Fibrinogen to fibrin transformation. In: Seegers WH, editor. Blood Clotting Enzymology. New York-London: Academic Press; 1967. p. 143-215.
5. Leshner AI. Molecular mechanisms of cocaine addiction. N Engl J Med. In Press 1996.
(e) Tables and Figures: Each Table should be typed on a separate page. Tables should supplement but not duplicate the text. A brief title should be provided for each. Abbreviations used in Tables should be defined. Legends to Tables should be typed double spaced on separate sheets and included at the end of the manuscript.
Figures should be submitted in triplicate and numbered in the order in which they are first mentioned in the text.
Figures should be in black and white, all details clear enough to permit reproduction without retouching, and legible in the actual size in which they should be published. High quality halftone pictures of figures should be supplied as glossy prints. On reverse side of all photographs clearly mark figure number, first author's name and correct orientation (top); use a light blue pencil as ink rubs off on other pictures. If the number of tables and/or figures is excessive, the author(s) could be asked to eliminate some of them. Authors requesting color figures will be required to share in their production expenses. Artwork and lettering must be done professionally. Figure Legends should be typewritten, double spaced, on separate sheets and included at the end of manuscript.
Authors are encouraged to submit illustrations electronically with the hard copy. Submitting illustrations in an electronic format helps Elsevier to produce and author's work to the best possible standards ensuring accuracy, clarity and a high level of detail. For more detailed specification on submitting electronic illustrations, please see the following webpage:
http://www.elsevier.com/locate/authorartwork
Peer Review: Regular Articles, Brief Communications, Mini-Reports and Mini-Reviews are subjected to review by two referees. Acceptance is based upon the significance, originality and validity of the material presented.
Checklist
1. Letter of submission. Please choose an Editor in a recent issue of Thrombosis Research.
2. Three hard copies of the manuscript and an electronic version on a diskette (optional).
a. Title page. Title of article, full Names(s) of Author(s), Affiliation of Author(s), Word count. Corresponding author. Address. Telephone, Fax and e-mail.
b. Abstract page (structured for original article) with six (6) Key Words and Abbreviations.
c. References (on separate sheets).
d. Tables (each on separate sheets).
e. Legends to Tables and Figures (on separate sheets)
f. Illustrations (high quality, three sets), labelled, and each set in a separate envelope.
3. Fax or mail a copy of the title page only with Editor's name to EEO.
Revised Manuscripts: When returning a revised manuscript to the Editor, provide a covering letter, replying to the Editor's and referees' comments, describing the changes which have been made in the revised version. Highlight the changes in the revised manuscript to facilitate editorial reassessment. Time for revision must never exceed 60 days.
Computer Disks if Submitting by Mail: Authors are encouraged to submit a 31/2" HD/DD computer disk to the Editor. Please observe the following criteria. Send only hard copy when first submitting your paper for acceptance and review. When you paper has been refereed, revised if necessary, and accepted, send a disk containing the final version, with the final hard copy. Make certain that the disk and hard copy match exactly. On the disk label, specify what software was used, including which release (e.g., WordPerfect 6.1) and specify what computer was used (IBM compatible PC, Apple Macintosh, etc.). The article file should include all textual material (text, references, tables, figure captions, etc.) and separate illustration files, if available. However, hard-copy figures should always be sent with the hard-copy manuscript. The file should follow the general instructions on style/arrangement and, in particular, the reference style of this journal as given in the Information for Authors. The file should be DOUBLE SPACED and should use the wrap around end of line feature, i.e., ONE HARD RETURN only at the end of each paragraph. Place TWO RETURNS after every element, such as Title, Headings, Paragraphs, Figure and Table Callouts. Be sure to keep a back-up disk for reference and safety.
III. GALLEY PROOFS.
Proofs are supplied for all articles. Authors are asked to return the proofs within 48 hours.Proofed manuscripts must always be accompanied by a signed "Transfer of Copyright Agreement" and a completed "Offprint Order Form." These forms are sent by the Publisher together with the galley proofs.
Offprints: Offprints can be ordered at prices quoted on the Offprint Order form. The corresponding author is provided 25 gratis offprints.
CONFLICT OF INTEREST
Authors must declare any conflict of interest, as outlined in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, on submission of a manuscript.
A conflict of interest for a given manuscript exists when a participant in the peer review and publication process - author, reviewer, editor - has ties to activites that could inappropriately influence his or her judgement, whether or not judgement is in fact affected. Financial relationships with industry (for example, through employment, consultancies, stock ownership, honoraria, expert testimony), either directly or through immediate family, are usually considered to be the most important conflicts of interest. However, conflicts can occur for other reasons, such as personal relationships, academic competition and intellectual passion. Public trust in the peer review process and the credibility of published articles depend in part on how well conflict of interest is handled during writing, peer review, and editorial decision making. Bias can often be identified and eliminated by careful attention to the scientific methods and conclusions of the work. Financial relationships and their effects are less easily detected than other conflicts of interest. Participants in peer review and publication should disclose their conflicting interests, and the information should be made available so that others can judge their effects for themselves.
(Uniform requirements for Manuscripts Submitted to Biomedical Journals, International Committee of Medical Journal Editors, http://www.icmje.org/index.htm )
Editorial Board
Editor in Chief for the Americas (USA, Canada, Mid - and South America):
J.S. Ginsberg, Mc Master University, Department of Medicine, 1200 Main Street West, HSC-3W11, Hamilton, Ontario L8N 3Z5, Canada; Tel: +1(905)521-2100 ext 6973, Email: thrombo@mcmaster.ca
Editor-in-Chief for the Rest of the world:
P.M. Sandset, Ulleval University Hospital, Department of Hematology, Hematological Research Lab., N-00407 Oslo, Norway; Tel: +47 221 19240/47, Fax: +47 221 19040, Email: thrombosis-research@ioks.uio.no
Associate Editors (Canada):
S. Bates, McMaster University Medical Centre, 1200 Main St. W, HSC-3W11, Hamilton ON L8N 3Z5, Canada
M. Crowther, St. Joseph's Hospital, 50 Charlton Ave E, Rm L:208, Hamilton ON L8N 4A6, Canada
S. Anand, McMaster University Medical Centre, 1200 Main St. W, HSC-3X28, Hamilton ON L8N 3Z5, Canada
J. Douketis, St. Joseph's Hospital, 50 Charlton Ave E, Fontbonne Building, Hamilton ON L8N 4A6, Canada
Associate Editors (Norway):
H. Arnesen, Dept. Cardiology, Ullevaal University Hospital, N-0407, Oslo, Norway
F. Wisloff, Dept. Hematology, Ullevaal University Hospital, N-0407, Oslo, Norway
P. Kierulf, Dept. Clinical Chemistry, Ullevaal University Hospital, N-0407, Oslo, Norway
U. Abildgaard, Dept. Medicine, Aker University Hospital, N-0514 Oslo, Norway
Editorial Board:
W. Ageno, Department of Internal Medicine, Ospedale di Circolo, University of Insubria, Varese, Italy
G. Agnelli, Sezione di Medicina Interna e Cardiovascolare, Dipartimento di Medicina Interna, Universita di Perugia, Perugia, Italy
N. Akar, Konutkent-2, Mudanya Sokak C-1 Blok, B Giris, Daire 2, Cayyolu 06530, Ankara, Turkey;
F. Bernardi, Dipartimento di Biochimica e Biologia Molecolare, Universita di Ferrara, Ferrara, Italy
E. Berntorp, Dept. of Coagulation Disorders, Dept. of Medicine, Lund University, Malmö General Hospital, SE-205 02 Malmö, Sweden; Email: se
F. Blasi, Dipartimento di Recerca Biologica e Tecnologica, Universit¨¢ Vita - Salute S. Raffaele, Via Olgettina 58, IT-20132 Milano, Italy;
N.A. Booth, Department of Molecular and Cell Biology, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD, UK;
E. Bovill, Department of Pathology, University of Vermont College of Medicine, Burlington, VT, USA
B. Brenner, Department of Haematology, Rambam Medical Centre, Haifa, Israel
W. Buczko, Department of Pharmacodynamics, Medical Academy in Bialystok, Michkiewicza Str 2C, Poland;
A. Chan, Henderson Research Center, Hamilton, ON, Canada
P. Comp, University Hospital at the VA Medical Center, Oklahoma City, OK, USA
Ph.G. De Groot, Univ. Hospital Utrecht, Dept. of Haematology (G03.647), PO Box 85500, Utrecht CX 3584, The Netherlands;
R. DelaCadena, Temple University School of Medicine, Philadelphia, PA, USA
C.E. Dempfle, Manheim University Hospital, 1, Department of Medicime, Theodore-Kutzer-Ufer 1-3, D-68167 Manheim, Germany;
A. Estelles, La Fe University Hospital, Research Center, ES-46009 Valencia, Spain;
D. Fitzgerald, Royal College of Surgeons in Ireland, Dublin, Ireland
C.W. Francis, University of Rochester Medical Center, Vascular Medicine Unit, Rochester, NY 14642, USA;
J. Francis, Clinical and Research Laboratories, Florida Hospital Cancer Institute, Orlando, FL, USA
D. Garcia, University of New Mexico, Albuquerque, NM, USA
J. George, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
H. Haller, Abteilung Nephrologie, Zentrum Innere Medizin und Dermatologie, Medizinische Hochschule Hannover, Carl-Neuberg-Straße 1, DE-30625 Hannover, Germany;
J. Heit, Hematology Research, Mayo Clinic, Rochester, MN, USA
K. Huber, Department of Cardiology, University of Vienna, Wachringer Guertel 18-20, Vienna, A-1090 Austria;
E. Hylek, General Medicine Division, Clinical Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA
J. Ingerslev, Department of Clinical Immunology, University Hospital Skejby, Aarhus, Denmark
S. Iwanaga, Department of Biology, Kyushu University 33, Fukuoka 812-8581, Japan
H. Kato, National Cardiovascular Centre Research Institute, Osaka, Japan
C. Kessler, Georgetown University Medical Center, Division of Hematology/Oncology, Lombardi Cancer Center, Washington DC, USA
L.M. Khachigian, Centre for Thrombosis and Vascular Research, School of Pathology, University of New South Wales, Sidney NSW 2052, Australia;
R. Lassila, Wihuri Research Institute, Kalliolinnantie 4, Fin-00140 Helsinki, Finland;
R. Lorenzet, Unit of Atherosclerosis and Thrombosis, Consorzlo Mario Negri Sud, Via Nazionale, I-66030 San Maria Imbaro (CH), Italy;
C. McCollum, Academic Surgery Unit, South Manchester University Hospital, Nell Lane, West Didsbury, Manchester M20 2LR, UK;
A. McNicol, Dept. Oral Biology, University of Manitoba, 780 Bannatyne Ave., Winnipeg, Manitoba, Canada R3E 0W2;
J.C.M. Meijers, Dept. Vascular Medicine, Academic Medical Center, P.O. Box 22660, 1100 DD Amsterdam, The Netherlands;
E. Mohler, University of Pensylvania School of Medicine, Presbyterian Medical Center, Philadelphia, PA, USA
P. Monagle, Division of Laboratory Services, Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia
M.W. Mosesson, The Blood Center of Southeastern Wisconsin, Blood Research Institute, P.O. Box 2178, Milwaukee, WI 53201-2178, USA;
L. Muszbek, Department of Clinical Biochemistry and Molecular Pathology, University Medical School, P.O. Box 40, HU-4012 Debrecen, Hungary;
P. Nurden, UMR 55333 CNRS, Laboratoire d'Hemobiologie, Hôpital Cardiologique, F-33604 Pessac, France;
F. Ofosu, Department of Pathology and Molecular Medicine, Health Sciences Center, McMaster University, Hamilton, ON, Canada
T. Ortel, Duke University, Durham, NC, USA
J.A. Paramo, Hematology Service, University Clinic of Navarra, 31080 Pamplona, Spain;
G. Pineo, Thrombosis Research Unit, Department of Internal Medicine, Foothills Hospital, Calgary, AB, Canada
M.L. Rand, Division of Haematology/Oncology, The Hospital for Sick Children, 555 University Ave., Toronto, Ontario, Canada M5G 1X8;
P.G. Rothberg, Director, Section of Molecular Diagnosis, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY 14642, USA
C. Ruan, Section of Thrombosis and Hemostasis, Jiangsu Institute of Hematology, Suzhou Medical College, 48 Renmin Road, Suzhou 215007, China;
S. Schulman, Koagulationsmottagningen, Department of Medicine, Karolinska Hospital, SE-171 76 Stockholm, Sweden;
A. Siegbhan, Laboratory for Coagulation Research, Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden
A. Takada, Dept. of Physiology, Hamamatsu University Medical School, 3600 Handa-Cho, Hamamatsu-Shi, Shizuoka-ken, 431 31 Japan;
H. Watzke, Universitätsklinik f¨¹ Innere Medizin I, Allgemeines Krankenhaus der Stadt Wien, Währinger G¨¹r A-1090 Vienna, Austria;
G. Werstuck, Department of Biochemistry and Medicine, McMaster University and the Henderson Research Centre, Hamilton, ON, Canada
R. White, UC Davis, Sacramento, CA, USA
|
刊名字顺( Alphabetical List of Journals):
返回页首 